Kypha: Funding, Investors & Team (Sep 2026)
Kypha is an early-stage life sciences company developing leading-edge technology and clinically useful products to improve the way autoimmune and inflammatory disorders are monitored and treated. With a core team of nine, plus an extensive network of scientific advisors, clinical collaborators and business mentors, Kypha has leveraged Federal grants and raised more than $3 million in private capital since 2011 to advance its lead diagnostic product – Comp Act Dx – toward FDA clearance and commercial launch in early 2014. Comp Act Dx is a simple yet revolutionary test that quickly measures the level of inflammation in the body – such as that caused by traumatic injury or autoimmune disease – with an unprecedented combination of speed and accuracy. Comp Act Dx is designed to allow superior monitoring of at-risk patients by measuring changes in inflammation in near-real time, thereby aiding medical professionals in making earlier, more effective clinical intervention decisions.
Kypha has raised $5.2M across 1 funding round on record, the most recent an undisclosed round of $5.2M announced in May 2022.
That round is below the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Kypha Company Profile and Key Stats
Latest funding round on record: May 2022.
Kypha Funding Rounds
Kypha Founders and Leadership Team
Contact details for the Kypha team: 1 of 1 has an email address on file.
Start 14-day free trial →Kypha Funding Compared to Other Biotechnology Startups
Kypha's latest round of $5.2M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Kypha in Biotechnology and Saint Louis
Companies Similar to Kypha
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Kypha Funding FAQs
What does Kypha do?
Kypha is an early-stage life sciences company developing leading-edge technology and clinically useful products to improve the way autoimmune and inflammatory disorders are monitored and treated. With a core team of nine, plus an extensive network of scientific advisors, clinical collaborators and business mentors, Kypha has leveraged Federal grants and raised more than $3 million in private capital since 2011 to advance its lead diagnostic product – Comp Act Dx – toward FDA clearance and commercial launch in early 2014. Comp Act Dx is a simple yet revolutionary test that quickly measures the level of inflammation in the body – such as that caused by traumatic injury or autoimmune disease – with an unprecedented combination of speed and accuracy. Comp Act Dx is designed to allow superior monitoring of at-risk patients by measuring changes in inflammation in near-real time, thereby aiding medical professionals in making earlier, more effective clinical intervention decisions.
How much funding has Kypha raised?
Kypha has raised $5.2M across 1 round on record. The most recent is an undisclosed round of $5.2M announced in May 2022.
When did Kypha last raise funding?
Kypha's most recent funding round on record is an undisclosed round of $5.2M, announced in May 2022.
Who is the CEO of Kypha?
Chad Stiening is listed as CEO at Kypha.
Where is Kypha headquartered?
Kypha is based in Saint Louis, Missouri, United States.
How many employees does Kypha have?
Kypha is in the 1-10 employee band.
How does Kypha's funding compare to other Biotechnology startups?
Kypha's latest round of $5.2M is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's Kypha Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Kypha is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.